tiprankstipranks
Advertisement
Advertisement

HK:2511 Stock Latest News

HighTide Therapeutics Strengthens Board With Appointment of Veteran Audit Chairman
Company AnnouncementsHighTide Therapeutics Strengthens Board With Appointment of Veteran Audit Chairman
4d ago
2511
HighTide Therapeutics Details Board Composition and Committee Roles
PremiumCompany Announcements
HighTide Therapeutics Details Board Composition and Committee Roles
4d ago
2511
HighTide Therapeutics Grants HK$15 Million Connected-Party Loan to Founder-CEO
PremiumCompany Announcements
HighTide Therapeutics Grants HK$15 Million Connected-Party Loan to Founder-CEO
11d ago
2511
HighTide Therapeutics Highlights HTD1801’s Potential as Foundational CKM Therapy in 2025 Results
PremiumCompany Announcements
HighTide Therapeutics Highlights HTD1801’s Potential as Foundational CKM Therapy in 2025 Results
1M ago
2511
HighTide positions HTD1801 as potential foundational therapy for CKM diseases
PremiumCompany Announcements
HighTide positions HTD1801 as potential foundational therapy for CKM diseases
1M ago
2511
HighTide Therapeutics Sets March 27 Board Meeting to Approve 2025 Annual Results
PremiumCompany AnnouncementsHighTide Therapeutics Sets March 27 Board Meeting to Approve 2025 Annual Results
2M ago
2511
HighTide’s First NDA for Diabetes Drug HTD1801 Accepted by China’s NMPA
Premium
Company Announcements
HighTide’s First NDA for Diabetes Drug HTD1801 Accepted by China’s NMPA
2M ago
2511
HighTide Flags Trial Quality Issues After Completing Phase IIb MASH Study of HTD1801
Premium
Company Announcements
HighTide Flags Trial Quality Issues After Completing Phase IIb MASH Study of HTD1801
3M ago
2511
HighTide Therapeutics Names Veteran Cardiometabolic Leader Filip Surmont as Chief Medical Officer
PremiumCompany Announcements
HighTide Therapeutics Names Veteran Cardiometabolic Leader Filip Surmont as Chief Medical Officer
3M ago
2511
HighTide Therapeutics Sets Up Nomination Committee to Bolster Governance
PremiumCompany Announcements
HighTide Therapeutics Sets Up Nomination Committee to Bolster Governance
5M ago
2511
HighTide Therapeutics’ HTD1801 Outperforms in Phase III Trial
PremiumCompany Announcements
HighTide Therapeutics’ HTD1801 Outperforms in Phase III Trial
5M ago
2511
HighTide Therapeutics Showcases Renal Benefits of HTD1801 at ASN Meeting
PremiumCompany Announcements
HighTide Therapeutics Showcases Renal Benefits of HTD1801 at ASN Meeting
6M ago
2511
HighTide Therapeutics Reports Positive Phase III Results for HTD1801 in Diabetes Treatment
PremiumCompany AnnouncementsHighTide Therapeutics Reports Positive Phase III Results for HTD1801 in Diabetes Treatment
6M ago
2511
Premium
Company Announcements
HighTide Therapeutics Reports Promising Interim Results for 2025
9M ago
2511
Premium
Company Announcements
HighTide Therapeutics Partners with Chinese Academy for Metabolic Disease Research
9M ago
2511
PremiumCompany Announcements
HighTide Therapeutics to Review Interim Financial Results
9M ago
2511
PremiumCompany Announcements
HighTide Therapeutics Completes Successful Share Placement
10M ago
2511
PremiumCompany Announcements
HighTide Therapeutics Announces Unanimous Approval of AGM Resolutions
10M ago
2511
PremiumCompany Announcements
Hightide Therapeutics Announces New Share Placement to Fund Lead Compound Development
11M ago
2511
PremiumCompany AnnouncementsHighTide Therapeutics Announces Annual General Meeting and Key Resolutions
11M ago
2511
Premium
Company Announcements
HighTide Therapeutics’ HTD1801 Shows Promising Results in Phase 3 Trials for Type 2 Diabetes
1y ago
2511
Premium
Company Announcements
HighTide Therapeutics Reports Promising 2024 Results with Core Product HTD1801
1y ago
2511

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >